Want to see FEMY full AI Analyst Report?
FEMY Stock Chart & Stats
$2.85
-$0.08(-2.11%)
At close: 4:00 PM EDT
$2.85
-$0.08(-2.11%)
Day’s Range― - ―
52-Week Range$1.46 - $22.22
Previous Close$3.71
Volume35.27K
Average Volume (3M)86.84K
Market Cap
$13.99M
Enterprise Value$17.38M
Total Cash (Recent Filing)$1.44M
Total Debt (Recent Filing)$4.79M
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Nov 17, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.56
Shares Outstanding8,375,027
10 Day Avg. Volume102,974
30 Day Avg. Volume86,840
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)3.88
Price to Sales (P/S)9.93
P/FCF Ratio-1.19
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue7.56
Enterprise Value/Gross Profit14.49
Enterprise Value/Ebitda-1.80
Forecast
1Y Price Target
$10.00Price Target Upside250.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.26
Revenue Forecast (FY)$2.83M
Bulls Say, Bears Say
Bulls Say
Expanded FemBloc Clinical ProgramExpanding the pivotal trial to twelve sites, including prominent academic centers, strengthens Femasys’ clinical execution capacity and geographic reach. Continued enrollment progress can support regulatory development of FemBloc and broaden the company’s potential women’s health product platform over the next several quarters.
Improved Near-term LiquidityThe $30 million financing provides additional liquidity for clinical programs and commercial activities while the company remains cash-flow negative. This funding can extend operational flexibility over the next several quarters, helping Femasys continue developing products and pursuing market adoption despite its current scale.
Focused Women’s Health Product PlatformFemasys operates across diagnostic, fertility and gynecologic procedures rather than relying on a single device concept. Its use of procedure-related products and disposables creates opportunities for account expansion, repeat utilization and broader commercialization as clinical adoption develops.
Bears Say
Severe Unprofitability And Limited ScaleLosses remain extremely large relative to revenue, showing that Femasys has not yet achieved the operating scale needed to support its cost base. Although losses improved versus earlier periods, the persistent imbalance limits financial resilience and makes a sustained path to profitability dependent on substantial growth.
Heavy And Worsening Cash BurnThe company is consuming cash at a rate far above its current revenue generation, creating an ongoing need to fund operations externally. Persistent negative operating and free cash flow can constrain investment choices and raise financing requirements unless commercialization produces materially stronger cash generation.
Weakened Balance Sheet And Rising LeverageHigher leverage combined with a sharp reduction in equity indicates reduced balance-sheet flexibility after ongoing losses. This leaves less capacity to absorb execution setbacks or fund growth internally, while dependence on debt and external capital can increase financing pressure over the medium term.
Femasys News
FEMY FAQ
What was Femasys’s price range in the past 12 months?
Femasys lowest stock price was $1.46 and its highest was $22.22 in the past 12 months.
What is Femasys’s market cap?
Femasys’s market cap is $13.99M.
When is Femasys’s upcoming earnings report date?
Femasys’s upcoming earnings report date is Nov 17, 2026 which is in 27 days.
How were Femasys’s earnings last quarter?
Femasys released its earnings results on Aug 14, 2026. The company reported -$1.33 earnings per share for the quarter, missing the consensus estimate of -$1.31 by -$0.02.
Is Femasys overvalued?
According to Wall Street analysts Femasys’s price is currently Undervalued.
Does Femasys pay dividends?
Femasys does not currently pay dividends.
What is Femasys’s EPS estimate?
Femasys’s EPS estimate is -0.47.
How many shares outstanding does Femasys have?
Femasys has 8,375,027 shares outstanding.
What happened to Femasys’s price movement after its last earnings report?
Femasys reported an EPS of -$1.33 in its last earnings report, missing expectations of -$1.31. Following the earnings report the stock price went down -5.677%.
Which hedge fund is a major shareholder of Femasys?
Currently, no hedge funds are holding shares in FEMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Femasys
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
FEMY Stock 12 Month Forecast
Average Price Target
$10.00
▲(250.88% Upside)
Technical Analysis
Retractable Technologies
―
Milestone Scientific
―
Precision Optics Corporation
―
NexGel Inc
―
―
Ownership Overview
15.04% Insiders
18.90% Mutual Funds
22.30% Other Institutional Investors
43.02% Public Companies and
Individual Investors